StockData

InfuSystem vs IRadimed

INFU and IRMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INFU and IRMD compare

IRadimed is the larger company, worth 3.7 times as much as InfuSystem ($1.1B against $295M).

On earnings, InfuSystem is cheaper: it trades at 36.1× trailing earnings, against 45.4× for IRadimed.

IRadimed grew revenue faster over the last twelve months (11.0% versus 2.5% for InfuSystem).

IRadimed keeps more of each dollar of sales as profit, with a net margin of 26.8% compared with 6.0% at InfuSystem.

IRadimed pays a dividend yielding 0.94%; InfuSystem does not pay one.

IRadimed scores higher on the StockData Score (19 against 13 for InfuSystem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINFUIRMD
Size and price
Market cap$295M$1.1B
Share price$14.79$84.84
Change, 1 year45.6%0.40%
Change, 5 years−13.4%101%
Beta (5Y)0.84−0.04
Employees473166
StockData Score
Total score1319 (better)
Valuation score1 (better)0
Growth score24 (better)
Performance score46 (better)
Health score66
Dividend score03 (better)
Valuation
P/E36.1× (better)45.4×
P/S2.1× (better)12.1×
P/B5.0× (better)10.2×
EV/EBITDA11.9× (better)33.5×
P/FCF12.9× (better)41.5×
PEG–2.30
FCF yield7.8% (better)2.4%
Fair value$14.53$54.13
Margin of safety−1.8% (better)−56.7%
Growth
Revenue growth (TTM)2.5%11.0% (better)
Revenue growth, 5Y average8.1%21.5% (better)
Net income growth (TTM)68.4% (better)13.2%
EPS growth (TTM)78.3% (better)13.3%
EPS growth, 5Y average−17.3%73.9% (better)
Profitability
Gross margin57.5%75.5% (better)
Operating margin9.3%32.3% (better)
Net margin6.0%26.8% (better)
FCF margin16.0%29.3% (better)
Return on equity15.0%23.4% (better)
Return on invested capital11.7%52.3% (better)
Financial health
Debt / equity0.35 (better)0.00
Net debt / EBITDA0.74–
Interest coverage12.1×–
Current ratio2.508.99 (better)
Altman Z-score5.9147.74 (better)
Piotroski F-score8 (better)6
Dividends and buybacks
Dividend yield–0.94%
Payout ratio–67.6%
Buyback yield2.7%–
Shareholder yield2.7% (better)0.94%
Ownership
Held by institutions79.1%61.4%
Held by insiders12.2%35.5%
Insider net buying, 12 months$150K (better)−$16.0M
Short interest, % of float3.9%7.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.